PB vs Industry: CRSP is overvalued based on its PB Ratio (2.1x) compared to the US Biotechs industry average (1.8x)....
crispr stock
Top 10 Owners of CRISPR Therapeutics AG Stockholder Stake Shares owned Capital Research & Management Co. … 4.66% 3,591,160 Loomis,...
Out of 9 analysts, 4 (44.44%) are recommending CRSP as a Strong Buy, 1 (11.11%) are recommending CRSP as a...
Rising research and development (R&D) expenses have led to expanding losses for CRISPR Therapeutics, and the relatively nascent state of...